ID   PPIA_HUMAN              Reviewed;         165 AA.
AC   P62937; A8K220; P05092; Q3KQW3; Q567Q0; Q6IBU5; Q96IX3; Q9BRU4; Q9BTY9;
AC   Q9UC61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JAN-2026, entry version 211.
DE   RecName: Full=Peptidyl-prolyl cis-trans isomerase A;
DE            Short=PPIase A;
DE            EC=5.2.1.8 {ECO:0000269|PubMed:2001362, ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:21593166, ECO:0000269|PubMed:25678563, ECO:0000305|PubMed:19207730, ECO:0000305|PubMed:26095851};
DE   AltName: Full=Cyclophilin A;
DE   AltName: Full=Cyclosporin A-binding protein;
DE   AltName: Full=Rotamase A;
DE   Contains:
DE     RecName: Full=Peptidyl-prolyl cis-trans isomerase A, N-terminally processed;
GN   Name=PPIA; Synonyms=CYPA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Leukemic T-cell;
RX   PubMed=3297675; DOI=10.1002/j.1460-2075.1987.tb04843.x;
RA   Haendler B., Hofer-Warbinek R., Hofer E.;
RT   "Complementary DNA for human T-cell cyclophilin.";
RL   EMBO J. 6:947-950(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2197089; DOI=10.1111/j.1432-1033.1990.tb15598.x;
RA   Haendler B., Hofer E.;
RT   "Characterization of the human cyclophilin gene and of related processed
RT   pseudogenes.";
RL   Eur. J. Biochem. 190:477-482(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Subthalamic nucleus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Blood, Bone marrow, Brain, Cervix, Colon, Lung, Skeletal
RC   muscle, Skin, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 2-30.
RX   PubMed=7657784; DOI=10.1093/oxfordjournals.humrep.a136138;
RA   Meier U., Beier-Hellwig K., Klug J., Linder D., Beier H.M.;
RT   "Identification of cyclophilin A from human decidual and placental tissue
RT   in the first trimester of pregnancy.";
RL   Hum. Reprod. 10:1305-1310(1995).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-31; 56-69; 77-118; 132-144 AND 155-165, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-28, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   VAL-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   TRP-121.
RX   PubMed=2001362; DOI=10.1021/bi00223a003;
RA   Liu J., Chen C.-M., Walsh C.T.;
RT   "Human and Escherichia coli cyclophilins: sensitivity to inhibition by the
RT   immunosuppressant cyclosporin A correlates with a specific tryptophan
RT   residue.";
RL   Biochemistry 30:2306-2310(1991).
RN   [14]
RP   INTERACTION WITH HIV-1 CAPSID PROTEIN (MICROBIAL INFECTION).
RX   PubMed=8513493; DOI=10.1016/0092-8674(93)90637-6;
RA   Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P.;
RT   "Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A
RT   and B.";
RL   Cell 73:1067-1078(1993).
RN   [15]
RP   INTERACTION WITH BSG.
RX   PubMed=11353871; DOI=10.1073/pnas.111583198;
RA   Pushkarsky T., Zybarth G., Dubrovsky L., Yurchenko V., Tang H., Guo H.,
RA   Toole B., Sherry B., Bukrinsky M.;
RT   "CD147 facilitates HIV-1 infection by interacting with virus-associated
RT   cyclophilin A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6360-6365(2001).
RN   [16]
RP   FUNCTION, INTERACTION WITH BSG, AND MUTAGENESIS OF PHE-60; PHE-113; TRP-121
RP   AND HIS-126.
RX   PubMed=11943775; DOI=10.1074/jbc.m201593200;
RA   Yurchenko V., Zybarth G., O'Connor M., Dai W.W., Franchin G., Hao T.,
RA   Guo H., Hung H.C., Toole B., Gallay P., Sherry B., Bukrinsky M.;
RT   "Active site residues of cyclophilin A are crucial for its signaling
RT   activity via CD147.";
RL   J. Biol. Chem. 277:22959-22965(2002).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [18]
RP   FUNCTION.
RX   PubMed=15130913; DOI=10.1161/01.atv.0000130664.51010.28;
RA   Jin Z.G., Lungu A.O., Xie L., Wang M., Wong C., Berk B.C.;
RT   "Cyclophilin A is a proinflammatory cytokine that activates endothelial
RT   cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 24:1186-1191(2004).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH BSG, AND INTERACTION WITH
RP   SARS-COV NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=15688292; DOI=10.1086/427811;
RA   Chen Z., Mi L., Xu J., Yu J., Wang X., Jiang J., Xing J., Shang P.,
RA   Qian A., Li Y., Shaw P.X., Wang J., Duan S., Ding J., Fan C., Zhang Y.,
RA   Yang Y., Yu X., Feng Q., Li B., Yao X., Zhang Z., Li L., Xue X., Zhu P.;
RT   "Function of HAb18G/CD147 in invasion of host cells by severe acute
RT   respiratory syndrome coronavirus.";
RL   J. Infect. Dis. 191:755-760(2005).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16527992; DOI=10.1161/01.res.0000216405.85080.a6;
RA   Suzuki J., Jin Z.G., Meoli D.F., Matoba T., Berk B.C.;
RT   "Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle
RT   cells.";
RL   Circ. Res. 98:811-817(2006).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND VAL-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   FUNCTION, INTERACTION WITH INFLUENZA A VIRUS MATRIX PROTEIN 1 (MICROBIAL
RP   INFECTION), CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-55.
RX   PubMed=19207730; DOI=10.1111/j.1462-5822.2009.01286.x;
RA   Liu X., Sun L., Yu M., Wang Z., Xu C., Xue Q., Zhang K., Ye X.,
RA   Kitamura Y., Liu W.;
RT   "Cyclophilin A interacts with influenza A virus M1 protein and impairs the
RT   early stage of the viral replication.";
RL   Cell. Microbiol. 11:730-741(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-28; LYS-44; LYS-76; LYS-82;
RP   LYS-125 AND LYS-131, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [24]
RP   INTERACTION WITH MEASLES VIRUS NUCLEOPROTEIN (MICROBIAL INFECTION).
RX   PubMed=20147391; DOI=10.1128/jvi.02168-09;
RA   Watanabe A., Yoneda M., Ikeda F., Terao-Muto Y., Sato H., Kai C.;
RT   "CD147/EMMPRIN acts as a functional entry receptor for measles virus on
RT   epithelial cells.";
RL   J. Virol. 84:4183-4193(2010).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TRP-121.
RX   PubMed=20676357; DOI=10.1371/journal.pbio.1000439;
RA   Davis T.L., Walker J.R., Campagna-Slater V., Finerty P.J., Paramanathan R.,
RA   Bernstein G., MacKenzie F., Tempel W., Ouyang H., Lee W.H.,
RA   Eisenmesser E.Z., Dhe-Paganon S.;
RT   "Structural and biochemical characterization of the human cyclophilin
RT   family of peptidyl-prolyl isomerases.";
RL   PLoS Biol. 8:E1000439-E1000439(2010).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-93, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH BSG, AND MUTAGENESIS OF
RP   ARG-55; ARG-69; HIS-70 AND THR-107.
RX   PubMed=21245143; DOI=10.1074/jbc.c110.181347;
RA   Song F., Zhang X., Ren X.B., Zhu P., Xu J., Wang L., Li Y.F., Zhong N.,
RA   Ru Q., Zhang D.W., Jiang J.L., Xia B., Chen Z.N.;
RT   "Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl
RT   cis-trans isomerase activity: direct binding between CyPA and the
RT   ectodomain of CD147.";
RL   J. Biol. Chem. 286:8197-8203(2011).
RN   [29]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH HCV NS5A (MICROBIAL
RP   INFECTION), CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-126.
RX   PubMed=21593166; DOI=10.1128/jvi.00393-11;
RA   Foster T.L., Gallay P., Stonehouse N.J., Harris M.;
RT   "Cyclophilin A interacts with domain II of hepatitis C virus NS5A and
RT   stimulates RNA binding in an isomerase-dependent manner.";
RL   J. Virol. 85:7460-7464(2011).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [31]
RP   FUNCTION.
RX   PubMed=22347431; DOI=10.1371/journal.pone.0031063;
RA   Liu X., Zhao Z., Xu C., Sun L., Chen J., Zhang L., Liu W.;
RT   "Cyclophilin A restricts influenza A virus replication through degradation
RT   of the M1 protein.";
RL   PLoS ONE 7:e31063-e31063(2012).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [33]
RP   FUNCTION.
RX   PubMed=23180369; DOI=10.1007/s10753-012-9578-7;
RA   Wei Y., Jinchuan Y., Yi L., Jun W., Zhongqun W., Cuiping W.;
RT   "Antiapoptotic and proapoptotic signaling of cyclophilin A in endothelial
RT   cells.";
RL   Inflammation 36:567-572(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH
RP   MAP3K5, AND MUTAGENESIS OF ARG-55.
RX   PubMed=26095851; DOI=10.1016/j.bbrc.2015.06.078;
RA   Kim H., Oh Y., Kim K., Jeong S., Chon S., Kim D., Jung M.H., Pak Y.K.,
RA   Ha J., Kang I., Choe W.;
RT   "Cyclophilin A regulates JNK/p38-MAPK signaling through its physical
RT   interaction with ASK1.";
RL   Biochem. Biophys. Res. Commun. 464:112-117(2015).
RN   [37]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TARDBP; HNRNPA1; HNRNPA2B1;
RP   HNRNPC; RBMX; HNRNPK AND HNRNPM, SUBCELLULAR LOCATION, ACETYLATION AT
RP   LYS-125, AND MUTAGENESIS OF ARG-55 AND LYS-125.
RX   PubMed=25678563; DOI=10.1093/brain/awv005;
RA   Lauranzano E., Pozzi S., Pasetto L., Stucchi R., Massignan T., Paolella K.,
RA   Mombrini M., Nardo G., Lunetta C., Corbo M., Mora G., Bendotti C.,
RA   Bonetto V.;
RT   "Peptidylprolyl isomerase A governs TARDBP function and assembly in
RT   heterogeneous nuclear ribonucleoprotein complexes.";
RL   Brain 138:974-991(2015).
RN   [38]
RP   ACETYLATION AT VAL-2, AND CLEAVAGE OF INITIATOR METHIONINE.
RX   PubMed=25489052; DOI=10.1093/hmg/ddu611;
RA   Myklebust L.M., Van Damme P., Stoeve S.I., Doerfel M.J., Abboud A.,
RA   Kalvik T.V., Grauffel C., Jonckheere V., Wu Y., Swensen J., Kaasa H.,
RA   Liszczak G., Marmorstein R., Reuter N., Lyon G.J., Gevaert K., Arnesen T.;
RT   "Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-
RT   acetylation defects.";
RL   Hum. Mol. Genet. 24:1956-1976(2015).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 AND VAL-2, CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-28 AND LYS-82, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [41]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH M.GENITALIUM ADHESIN P140
RP   (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION.
RX   PubMed=29551599; DOI=10.1016/j.ijmm.2018.03.001;
RA   Deng X., Dai P., Yu M., Chen L., Zhu C., You X., Li L., Zeng Y.;
RT   "Cyclophilin A is the potential receptor of the Mycoplasma genitalium
RT   adhesion protein.";
RL   Int. J. Med. Microbiol. 308:405-412(2018).
RN   [42]
RP   FUNCTION.
RX   PubMed=30328013; DOI=10.1007/s12250-018-0058-6;
RA   Mahesutihan M., Zheng W., Cui L., Li Y., Jiao P., Yang W., Liu W., Li J.,
RA   Fan W., Yang L., Liu W., Sun L.;
RT   "CypA Regulates AIP4-Mediated M1 Ubiquitination of Influenza A Virus.";
RL   Virol. Sin. 33:440-448(2018).
RN   [43]
RP   FUNCTION, AND INTERACTION WITH FOXO1.
RX   PubMed=31063815; DOI=10.1016/j.cellsig.2019.04.014;
RA   Xie Y., Li X., Ge J.;
RT   "Cyclophilin A-FoxO1 signaling pathway in endothelial cell apoptosis.";
RL   Cell. Signal. 61:57-65(2019).
RN   [44]
RP   FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION (MICROBIAL
RP   INFECTION).
RX   PubMed=33013867; DOI=10.3389/fimmu.2020.02052;
RA   Li L., Luo D., Liao Y., Peng K., Zeng Y.;
RT   "Mycoplasma genitalium Protein of Adhesion Induces Inflammatory Cytokines
RT   via Cyclophilin A-CD147 Activating the ERK-NF-kappaB Pathway in Human
RT   Urothelial Cells.";
RL   Front. Immunol. 11:2052-2052(2020).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS), AND STRUCTURE BY NMR.
RX   PubMed=1896075; DOI=10.1038/353276a0;
RA   Kallen J., Spitzfaden C., Zurini M.G.M., Wider G., Widmer H., Wuethrich K.,
RA   Walkinshaw M.D.;
RT   "Structure of human cyclophilin and its binding site for cyclosporin A
RT   determined by X-ray crystallography and NMR spectroscopy.";
RL   Nature 353:276-279(1991).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   PubMed=1946361; DOI=10.1073/pnas.88.21.9483;
RA   Ke H., Zydowsky L.D., Liu J., Walsh C.T.;
RT   "Crystal structure of recombinant human T-cell cyclophilin A at 2.5-A
RT   resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9483-9487(1991).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH CYCLOPHILIN.
RX   PubMed=8421501; DOI=10.1038/361091a0;
RA   Pfuegl G., Kallen J., Schirmer T., Jansonius J.N., Zurini M.G.M.,
RA   Walkinshaw M.D.;
RT   "X-ray structure of a decameric cyclophilin-cyclosporin crystal complex.";
RL   Nature 361:91-94(1993).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
RX   PubMed=8263916; DOI=10.1006/jmbi.1993.1664;
RA   Mikol V., Kallen J., Pfluegl G., Walkinshaw M.D.;
RT   "X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex
RT   at 2.1-A resolution.";
RL   J. Mol. Biol. 234:1119-1130(1993).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=8652511; DOI=10.1021/bi9602775;
RA   Zhao Y., Ke H.;
RT   "Crystal structure implies that cyclophilin predominantly catalyzes the
RT   trans to cis isomerization.";
RL   Biochemistry 35:7356-7361(1996).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.58 ANGSTROMS).
RX   PubMed=9385632; DOI=10.1002/pro.5560061103;
RA   Vajdos F.F., Yoo S., Houseweart M., Sundquist W.I., Hill C.P.;
RT   "Crystal structure of cyclophilin A complexed with a binding site peptide
RT   from the HIV-1 capsid protein.";
RL   Protein Sci. 6:2297-2307(1997).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS).
RX   PubMed=9769216; DOI=10.1006/jmbi.1998.2108;
RA   Kallen J., Mikol V., Taylor P., Walkinshaw M.D.;
RT   "X-ray structures and analysis of 11 cyclosporin derivatives complexed with
RT   cyclophilin A.";
RL   J. Mol. Biol. 283:435-449(1998).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH PPP3CA.
RX   PubMed=12218175; DOI=10.1073/pnas.192206699;
RA   Huai Q., Kim H.Y., Liu Y., Zhao Y., Mondragon A., Liu J.O., Ke H.;
RT   "Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but
RT   distinct recognition of immunophilin-drug complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12037-12042(2002).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) IN COMPLEX WITH PPP3CA.
RX   PubMed=12357034; DOI=10.1073/pnas.212504399;
RA   Jin L., Harrison S.C.;
RT   "Crystal structure of human calcineurin complexed with cyclosporin A and
RT   human cyclophilin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13522-13526(2002).
RN   [54]
RP   STRUCTURE BY NMR OF COMPLEX WITH CYCLOPHILIN.
RX   PubMed=8421500; DOI=10.1038/361088a0;
RA   Theriault Y., Logan T.M., Meadows R., Yu L., Olejniczak E.T., Holzman T.F.,
RA   Simmer R.L., Fesik S.W.;
RT   "Solution structure of the cyclosporin A/cyclophilin complex by NMR.";
RL   Nature 361:88-91(1993).
RN   [55]
RP   STRUCTURE BY NMR.
RX   PubMed=9299338; DOI=10.1006/jmbi.1997.1220;
RA   Ottiger M., Zerbe O., Guentert P., Wuethrich K.;
RT   "The NMR solution conformation of unligated human cyclophilin A.";
RL   J. Mol. Biol. 272:64-81(1997).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) ALONE AND IN COMPLEX WITH
RP   CYCLOSPORINE AND HIV-1 CAPSID, AND ACETYLATION AT LYS-125.
RX   PubMed=20364129; DOI=10.1038/nchembio.342;
RA   Lammers M., Neumann H., Chin J.W., James L.C.;
RT   "Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV
RT   isomerization.";
RL   Nat. Chem. Biol. 6:331-337(2010).
CC   -!- FUNCTION: Catalyzes the cis-trans isomerization of proline imidic
CC       peptide bonds in oligopeptides (PubMed:2001362, PubMed:20676357,
CC       PubMed:21245143, PubMed:21593166, PubMed:25678563). Exerts a strong
CC       chemotactic effect on leukocytes partly through activation of one of
CC       its membrane receptors BSG/CD147, initiating a signaling cascade that
CC       culminates in MAPK/ERK activation (PubMed:11943775, PubMed:21245143).
CC       Activates endothelial cells (ECs) in a pro-inflammatory manner by
CC       stimulating activation of NF-kappa-B and ERK, JNK and p38 MAP-kinases
CC       and by inducing expression of adhesion molecules including SELE and
CC       VCAM1 (PubMed:15130913). Induces apoptosis in ECs by promoting the
CC       FOXO1-dependent expression of CCL2 and BCL2L11 which are involved in
CC       EC chemotaxis and apoptosis (PubMed:31063815). In response to oxidative
CC       stress, initiates proapoptotic and antiapoptotic signaling in ECs via
CC       activation of NF-kappa-B and AKT1 and up-regulation of antiapoptotic
CC       protein BCL2 (PubMed:23180369). Negatively regulates MAP3K5/ASK1 kinase
CC       activity, autophosphorylation and oxidative stress-induced apoptosis
CC       mediated by MAP3K5/ASK1 (PubMed:26095851). Necessary for the assembly
CC       of TARDBP in heterogeneous nuclear ribonucleoprotein (hnRNP) complexes
CC       and regulates TARDBP binding to RNA UG repeats and TARDBP-dependent
CC       expression of HDAC6, ATG7 and VCP which are involved in clearance of
CC       protein aggregates (PubMed:25678563). Plays an important role in
CC       platelet activation and aggregation (By similarity). Regulates calcium
CC       mobilization and integrin ITGA2B:ITGB3 bidirectional signaling via
CC       increased ROS production as well as by facilitating the interaction
CC       between integrin and the cell cytoskeleton (By similarity). Binds
CC       heparan sulfate glycosaminoglycans (PubMed:11943775). Inhibits
CC       replication of influenza A virus (IAV) (PubMed:19207730). Inhibits
CC       ITCH/AIP4-mediated ubiquitination of matrix protein 1 (M1) of IAV by
CC       impairing the interaction of ITCH/AIP4 with M1, followed by the
CC       suppression of the nuclear export of M1, and finally reduction of the
CC       replication of IAV (PubMed:22347431, PubMed:30328013).
CC       {ECO:0000250|UniProtKB:P17742, ECO:0000269|PubMed:11943775,
CC       ECO:0000269|PubMed:15130913, ECO:0000269|PubMed:19207730,
CC       ECO:0000269|PubMed:2001362, ECO:0000269|PubMed:20676357,
CC       ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:21593166,
CC       ECO:0000269|PubMed:22347431, ECO:0000269|PubMed:23180369,
CC       ECO:0000269|PubMed:25678563, ECO:0000269|PubMed:26095851,
CC       ECO:0000269|PubMed:30328013, ECO:0000269|PubMed:31063815}.
CC   -!- FUNCTION: (Microbial infection) May act as a mediator between human
CC       SARS coronavirus nucleoprotein and BSG/CD147 in the process of invasion
CC       of host cells by the virus (PubMed:15688292).
CC       {ECO:0000269|PubMed:15688292}.
CC   -!- FUNCTION: (Microbial infection) Stimulates RNA-binding ability of HCV
CC       NS5A in a peptidyl-prolyl cis-trans isomerase activity-dependent
CC       manner. {ECO:0000269|PubMed:21593166}.
CC   -!- FUNCTION: (Microbial infection) May act as a receptor for M.genitalium
CC       adhesin protein P140 (also called MgPa) (PubMed:29551599,
CC       PubMed:33013867). {ECO:0000305|PubMed:29551599,
CC       ECO:0000305|PubMed:33013867}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[protein]-peptidylproline (omega=180) = [protein]-
CC         peptidylproline (omega=0); Xref=Rhea:RHEA:16237, Rhea:RHEA-
CC         COMP:10747, Rhea:RHEA-COMP:10748, ChEBI:CHEBI:83833,
CC         ChEBI:CHEBI:83834; EC=5.2.1.8; Evidence={ECO:0000269|PubMed:2001362,
CC         ECO:0000269|PubMed:20676357, ECO:0000269|PubMed:21245143,
CC         ECO:0000269|PubMed:21593166, ECO:0000269|PubMed:25678563,
CC         ECO:0000305|PubMed:19207730, ECO:0000305|PubMed:26095851};
CC   -!- ACTIVITY REGULATION: Binds cyclosporin A (CsA). CsA mediates some of
CC       its effects via an inhibitory action on PPIase.
CC       {ECO:0000269|PubMed:2001362}.
CC   -!- SUBUNIT: Interacts with protein phosphatase PPP3CA/calcineurin A
CC       (PubMed:12218175, PubMed:12357034). Interacts with PRPF19 isoform 2
CC       (via N-terminus) (By similarity). Interacts with isoform 2 of BSG/CD147
CC       (PubMed:11353871, PubMed:11943775, PubMed:15688292, PubMed:21245143).
CC       Interacts with FOXO1; the interaction promotes FOXO1 dephosphorylation,
CC       nuclear accumulation and transcriptional activity (PubMed:31063815).
CC       Interacts with integrin ITGA2B:ITGB3; the interaction is ROS and
CC       peptidyl-prolyl cis-trans isomerase (PPIase) activity-dependent and is
CC       increased in the presence of thrombin (By similarity). Interacts with
CC       MAP3K5 (PubMed:26095851). Interacts with TARDBP; the interaction is
CC       dependent on the RNA-binding activity of TARDBP and the PPIase activity
CC       of PPIA/CYPA and the acetylation of PPIA/CYPA at Lys-125 favors the
CC       interaction (PubMed:25678563). Interacts with HNRNPA1, HNRNPA2B1,
CC       HNRNPC, RBMX, HNRNPK and HNRNPM (PubMed:25678563).
CC       {ECO:0000250|UniProtKB:P17742, ECO:0000269|PubMed:11353871,
CC       ECO:0000269|PubMed:11943775, ECO:0000269|PubMed:12218175,
CC       ECO:0000269|PubMed:12357034, ECO:0000269|PubMed:15688292,
CC       ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:25678563,
CC       ECO:0000269|PubMed:26095851, ECO:0000269|PubMed:31063815}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 capsid protein
CC       (PubMed:20364129, PubMed:8513493). {ECO:0000269|PubMed:20364129,
CC       ECO:0000269|PubMed:8513493}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human SARS coronavirus
CC       nucleoprotein. {ECO:0000269|PubMed:15688292}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with measles virus
CC       nucleoprotein. {ECO:0000269|PubMed:20147391}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with influenza A virus matrix
CC       protein 1. {ECO:0000269|PubMed:19207730}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with M.genitalium adhesin P140
CC       protein (also called MgPa). {ECO:0000269|PubMed:29551599}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV NS5A; the interaction
CC       stimulates RNA-binding ability of NS5A and is dependent on the
CC       peptidyl-prolyl cis-trans isomerase activity of PPIA/CYPA.
CC       {ECO:0000269|PubMed:21593166}.
CC   -!- INTERACTION:
CC       P62937; P05067: APP; NbExp=4; IntAct=EBI-437708, EBI-77613;
CC       P62937; P35613: BSG; NbExp=2; IntAct=EBI-437708, EBI-750709;
CC       P62937; Q00535: CDK5; NbExp=3; IntAct=EBI-437708, EBI-1041567;
CC       P62937; P46108-1: CRK; NbExp=4; IntAct=EBI-437708, EBI-287556;
CC       P62937; O43614: HCRTR2; NbExp=3; IntAct=EBI-437708, EBI-25884102;
CC       P62937; O14686: KMT2D; NbExp=2; IntAct=EBI-437708, EBI-996065;
CC       P62937; Q8TBB1: LNX1; NbExp=3; IntAct=EBI-437708, EBI-739832;
CC       P62937; O75376: NCOR1; NbExp=3; IntAct=EBI-437708, EBI-347233;
CC       P62937; Q16849: PTPRN; NbExp=3; IntAct=EBI-437708, EBI-728153;
CC       P62937; P62841: RPS15; NbExp=3; IntAct=EBI-437708, EBI-372635;
CC       P62937; O00267: SUPT5H; NbExp=2; IntAct=EBI-437708, EBI-710464;
CC       P62937; Q72497: gag; Xeno; NbExp=7; IntAct=EBI-437708, EBI-1036263;
CC       P62937; P0DTC9: N; Xeno; NbExp=3; IntAct=EBI-437708, EBI-25475856;
CC       P62937; P59595: N; Xeno; NbExp=4; IntAct=EBI-437708, EBI-7602718;
CC       P62937; PRO_0000037309 [P0C6X7]: rep; Xeno; NbExp=4; IntAct=EBI-437708, EBI-25475797;
CC       P62937; PRO_0000045602 [Q99IB8]; Xeno; NbExp=2; IntAct=EBI-437708, EBI-6927873;
CC       P62937-2; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-25884072, EBI-5280499;
CC       P62937-2; Q14032: BAAT; NbExp=3; IntAct=EBI-25884072, EBI-8994378;
CC       P62937-2; Q6PH81: C16orf87; NbExp=3; IntAct=EBI-25884072, EBI-6598617;
CC       P62937-2; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-25884072, EBI-742887;
CC       P62937-2; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-25884072, EBI-13213391;
CC       P62937-2; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-25884072, EBI-618189;
CC       P62937-2; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-25884072, EBI-9088619;
CC       P62937-2; Q9NWQ4-1: GPATCH2L; NbExp=3; IntAct=EBI-25884072, EBI-11959863;
CC       P62937-2; P52597: HNRNPF; NbExp=3; IntAct=EBI-25884072, EBI-352986;
CC       P62937-2; Q02363: ID2; NbExp=3; IntAct=EBI-25884072, EBI-713450;
CC       P62937-2; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-25884072, EBI-743960;
CC       P62937-2; Q9BRX2: PELO; NbExp=3; IntAct=EBI-25884072, EBI-1043580;
CC       P62937-2; P07225: PROS1; NbExp=3; IntAct=EBI-25884072, EBI-2803380;
CC       P62937-2; Q13573: SNW1; NbExp=3; IntAct=EBI-25884072, EBI-632715;
CC       P62937-2; P56693: SOX10; NbExp=3; IntAct=EBI-25884072, EBI-1167533;
CC       P62937-2; Q13586: STIM1; NbExp=3; IntAct=EBI-25884072, EBI-448878;
CC       P62937-2; Q13033-2: STRN3; NbExp=3; IntAct=EBI-25884072, EBI-1053876;
CC       P62937-2; P15884: TCF4; NbExp=3; IntAct=EBI-25884072, EBI-533224;
CC       P62937-2; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-25884072, EBI-1390168;
CC       P62937-2; Q9UJA5: TRMT6; NbExp=3; IntAct=EBI-25884072, EBI-934061;
CC       P62937-2; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-25884072, EBI-12040603;
CC       P62937-2; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-25884072, EBI-14104088;
CC       P62937-2; Q15776: ZKSCAN8; NbExp=3; IntAct=EBI-25884072, EBI-2602314;
CC       P62937-2; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-25884072, EBI-12010736;
CC       P62937-2; O15535: ZSCAN9; NbExp=3; IntAct=EBI-25884072, EBI-751531;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:26095851,
CC       ECO:0000269|PubMed:29551599}. Secreted {ECO:0000269|PubMed:16527992}.
CC       Nucleus {ECO:0000269|PubMed:25678563, ECO:0000269|PubMed:29551599}.
CC       Cell membrane {ECO:0000269|PubMed:29551599}. Note=Secretion occurs in
CC       response to oxidative stress in vascular smooth muscle through a
CC       vesicular secretory pathway that includes Rho GTPase signaling, actin
CC       remodeling, and myosin II activation. {ECO:0000269|PubMed:16527992}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:33013867}.
CC       Note=(Microbial infection) Increased amounts of protein are secreted
CC       after treatment with M.genitalium P140 adhesin (MgPa).
CC       {ECO:0000269|PubMed:33013867}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P62937-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P62937-2; Sequence=VSP_056050;
CC   -!- PTM: Acetylation at Lys-125 markedly inhibits catalysis of cis to trans
CC       isomerization and stabilizes cis rather than trans forms of the HIV-1
CC       capsid. PPIA acetylation also antagonizes the immunosuppressive effects
CC       of cyclosporine by inhibiting the sequential steps of cyclosporine
CC       binding and calcineurin inhibition (PubMed:20364129, Ref.12).
CC       Acetylation at Lys-125 favors its interaction with TARDBP
CC       (PubMed:25678563). {ECO:0000269|PubMed:20364129,
CC       ECO:0000269|PubMed:25678563, ECO:0000269|Ref.12}.
CC   -!- SIMILARITY: Belongs to the cyclophilin-type PPIase family. PPIase A
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cyclophilin entry;
CC       URL="https://en.wikipedia.org/wiki/Cyclophilin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00052; CAA68264.1; -; mRNA.
DR   EMBL; X52851; CAA37039.1; -; Genomic_DNA.
DR   EMBL; AK290085; BAF82774.1; -; mRNA.
DR   EMBL; AK293003; BAF85692.1; -; mRNA.
DR   EMBL; CR456707; CAG32988.1; -; mRNA.
DR   EMBL; AB451307; BAG70121.1; -; mRNA.
DR   EMBL; AB451438; BAG70252.1; -; mRNA.
DR   EMBL; AY739283; AAU13906.1; -; Genomic_DNA.
DR   EMBL; AC004854; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC013436; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000689; AAH00689.1; -; mRNA.
DR   EMBL; BC003026; AAH03026.2; -; mRNA.
DR   EMBL; BC005320; AAH05320.1; -; mRNA.
DR   EMBL; BC005982; AAH05982.1; -; mRNA.
DR   EMBL; BC007104; AAH07104.1; -; mRNA.
DR   EMBL; BC013915; AAH13915.1; -; mRNA.
DR   EMBL; BC073992; AAH73992.1; -; mRNA.
DR   EMBL; BC093076; AAH93076.1; -; mRNA.
DR   EMBL; BC106030; AAI06031.1; -; mRNA.
DR   EMBL; BC137057; AAI37058.1; -; mRNA.
DR   EMBL; BC137058; AAI37059.1; -; mRNA.
DR   CCDS; CCDS5494.1; -. [P62937-1]
DR   CCDS; CCDS75592.1; -. [P62937-2]
DR   PIR; A94496; CSHUA.
DR   RefSeq; NP_001287910.1; NM_001300981.2. [P62937-2]
DR   RefSeq; NP_066953.1; NM_021130.5. [P62937-1]
DR   RefSeq; XP_047276492.1; XM_047420536.1. [P62937-2]
DR   RefSeq; XP_047276493.1; XM_047420537.1. [P62937-2]
DR   RefSeq; XP_054214491.1; XM_054358516.1. [P62937-2]
DR   PDB; 1AK4; X-ray; 2.36 A; A/B=1-165.
DR   PDB; 1AWQ; X-ray; 1.58 A; A=2-165.
DR   PDB; 1AWR; X-ray; 1.58 A; A/B/C/D/E/F=2-165.
DR   PDB; 1AWS; X-ray; 2.55 A; A=2-165.
DR   PDB; 1AWT; X-ray; 2.55 A; A/B/C/D/E/F=2-165.
DR   PDB; 1AWU; X-ray; 2.34 A; A=2-165.
DR   PDB; 1AWV; X-ray; 2.34 A; A/B/C/D/E/F=2-165.
DR   PDB; 1BCK; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWA; X-ray; 2.10 A; A=1-165.
DR   PDB; 1CWB; X-ray; 2.20 A; A=1-165.
DR   PDB; 1CWC; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWF; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWH; X-ray; 1.86 A; A=1-165.
DR   PDB; 1CWI; X-ray; 1.90 A; A=1-165.
DR   PDB; 1CWJ; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWK; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWL; X-ray; 1.80 A; A=1-165.
DR   PDB; 1CWM; X-ray; 2.00 A; A=1-165.
DR   PDB; 1CWO; X-ray; 1.86 A; A=1-165.
DR   PDB; 1FGL; X-ray; 1.80 A; A=1-165.
DR   PDB; 1M63; X-ray; 2.80 A; C/G=1-165.
DR   PDB; 1M9C; X-ray; 2.00 A; A/B=1-165.
DR   PDB; 1M9D; X-ray; 1.90 A; A/B=1-165.
DR   PDB; 1M9E; X-ray; 1.72 A; A/B=1-164.
DR   PDB; 1M9F; X-ray; 1.73 A; A/B=1-165.
DR   PDB; 1M9X; X-ray; 1.70 A; A/B/E/F=1-165.
DR   PDB; 1M9Y; X-ray; 1.90 A; A/B/E/F=1-165.
DR   PDB; 1MF8; X-ray; 3.10 A; C=1-165.
DR   PDB; 1MIK; X-ray; 1.76 A; A=1-165.
DR   PDB; 1NMK; X-ray; 2.10 A; A/B=1-165.
DR   PDB; 1OCA; NMR; -; A=1-165.
DR   PDB; 1RMH; X-ray; 2.40 A; A/B=2-165.
DR   PDB; 1VBS; X-ray; 2.00 A; A=1-165.
DR   PDB; 1VBT; X-ray; 2.30 A; A/B=1-165.
DR   PDB; 1W8L; X-ray; 1.80 A; A=2-165.
DR   PDB; 1W8M; X-ray; 1.65 A; A=2-165.
DR   PDB; 1W8V; X-ray; 1.70 A; A=2-165.
DR   PDB; 1YND; X-ray; 1.60 A; A/B=1-165.
DR   PDB; 1ZKF; X-ray; 2.55 A; A/B=1-165.
DR   PDB; 2ALF; X-ray; 1.90 A; A=2-165.
DR   PDB; 2CPL; X-ray; 1.63 A; A=1-165.
DR   PDB; 2CYH; X-ray; 1.64 A; A=2-165.
DR   PDB; 2MS4; NMR; -; A=1-165.
DR   PDB; 2MZU; NMR; -; A=1-165.
DR   PDB; 2N0T; NMR; -; A=1-165.
DR   PDB; 2RMA; X-ray; 2.10 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 2RMB; X-ray; 2.10 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 2X25; X-ray; 1.20 A; B=2-165.
DR   PDB; 2X2A; X-ray; 1.40 A; A/B=1-165.
DR   PDB; 2X2C; X-ray; 2.41 A; K/M/O/Q/S=1-165.
DR   PDB; 2X2D; X-ray; 1.95 A; B/C=1-165.
DR   PDB; 2XGY; X-ray; 1.80 A; B=1-165.
DR   PDB; 3CYH; X-ray; 1.90 A; A=2-165.
DR   PDB; 3CYS; NMR; -; A=1-165.
DR   PDB; 3K0M; X-ray; 1.25 A; A=1-165.
DR   PDB; 3K0N; X-ray; 1.39 A; A=1-165.
DR   PDB; 3K0O; X-ray; 1.55 A; A=1-165.
DR   PDB; 3K0P; X-ray; 1.65 A; A=1-165.
DR   PDB; 3K0Q; X-ray; 2.32 A; A=1-165.
DR   PDB; 3K0R; X-ray; 2.42 A; A=1-165.
DR   PDB; 3ODI; X-ray; 2.20 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 3ODL; X-ray; 2.31 A; A/C/E/G/I/K/M/O/Q/S=1-165.
DR   PDB; 3RDD; X-ray; 2.14 A; A=1-165.
DR   PDB; 4CYH; X-ray; 2.10 A; A=2-165.
DR   PDB; 4IPZ; X-ray; 1.67 A; A=1-165.
DR   PDB; 4N1M; X-ray; 1.15 A; A=1-165.
DR   PDB; 4N1N; X-ray; 1.50 A; A=1-165.
DR   PDB; 4N1O; X-ray; 1.75 A; A=1-165.
DR   PDB; 4N1P; X-ray; 1.90 A; A=1-165.
DR   PDB; 4N1Q; X-ray; 1.65 A; A=1-165.
DR   PDB; 4N1R; X-ray; 1.80 A; A=1-165.
DR   PDB; 4N1S; X-ray; 1.47 A; A=1-165.
DR   PDB; 4YUG; X-ray; 1.48 A; A=1-165.
DR   PDB; 4YUH; X-ray; 1.34 A; A=1-165.
DR   PDB; 4YUI; X-ray; 1.38 A; A=1-165.
DR   PDB; 4YUJ; X-ray; 1.42 A; A=1-165.
DR   PDB; 4YUK; X-ray; 1.48 A; A=1-165.
DR   PDB; 4YUL; X-ray; 1.42 A; A=1-165.
DR   PDB; 4YUM; X-ray; 1.50 A; A=1-165.
DR   PDB; 4YUN; X-ray; 1.58 A; A=1-165.
DR   PDB; 4YUO; X-ray; 1.20 A; A=1-165.
DR   PDB; 4YUP; X-ray; 1.75 A; A=1-165.
DR   PDB; 5CYH; X-ray; 2.10 A; A=2-165.
DR   PDB; 5F66; X-ray; 1.15 A; A=1-165.
DR   PDB; 5FJB; EM; 9.00 A; C=2-165.
DR   PDB; 5KUL; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUN; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUO; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUQ; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUR; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUS; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUU; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUV; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUW; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KUZ; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV0; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV1; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV2; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV3; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV4; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV5; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV6; X-ray; 1.70 A; A=2-165.
DR   PDB; 5KV7; X-ray; 1.70 A; A=2-165.
DR   PDB; 5LUD; X-ray; 1.25 A; A=1-165.
DR   PDB; 5NOQ; X-ray; 1.60 A; A=1-165.
DR   PDB; 5NOR; X-ray; 1.80 A; A=1-165.
DR   PDB; 5NOS; X-ray; 1.35 A; A=1-165.
DR   PDB; 5NOT; X-ray; 1.45 A; A=1-165.
DR   PDB; 5NOU; X-ray; 1.30 A; A=1-165.
DR   PDB; 5NOV; X-ray; 2.00 A; A=1-165.
DR   PDB; 5NOW; X-ray; 1.48 A; A=1-165.
DR   PDB; 5NOX; X-ray; 1.49 A; A=1-165.
DR   PDB; 5NOY; X-ray; 1.43 A; A=1-165.
DR   PDB; 5NOZ; X-ray; 1.61 A; A=1-165.
DR   PDB; 5T9U; X-ray; 2.30 A; A/B/C/D=1-164.
DR   PDB; 5T9W; X-ray; 2.00 A; A=2-165.
DR   PDB; 5T9Z; X-ray; 1.40 A; A=2-164.
DR   PDB; 5TA2; X-ray; 1.48 A; A=2-164.
DR   PDB; 5TA4; X-ray; 1.50 A; A=2-165.
DR   PDB; 5WC7; X-ray; 1.43 A; A=1-165.
DR   PDB; 6BTA; X-ray; 1.50 A; A=1-165.
DR   PDB; 6GJI; X-ray; 1.60 A; A=1-165.
DR   PDB; 6GJJ; X-ray; 1.38 A; A=1-165.
DR   PDB; 6GJL; X-ray; 1.16 A; A=1-165.
DR   PDB; 6GJM; X-ray; 1.35 A; A=1-165.
DR   PDB; 6GJN; X-ray; 1.70 A; A=1-165.
DR   PDB; 6GJP; X-ray; 1.94 A; A=1-165.
DR   PDB; 6GJR; X-ray; 1.69 A; A=1-165.
DR   PDB; 6GJY; X-ray; 1.29 A; A=1-165.
DR   PDB; 6GS6; X-ray; 1.16 A; A=1-165.
DR   PDB; 6I42; X-ray; 1.38 A; A=2-165.
DR   PDB; 6U5C; X-ray; 1.62 A; A=1-165.
DR   PDB; 6U5D; X-ray; 1.65 A; A=1-165.
DR   PDB; 6U5E; X-ray; 1.56 A; A=1-165.
DR   PDB; 6U5G; EM; 2.50 A; A=1-165.
DR   PDB; 6X3R; X-ray; 1.80 A; A=1-165.
DR   PDB; 6X3Y; X-ray; 1.40 A; A=1-165.
DR   PDB; 6X4M; X-ray; 1.50 A; A=1-165.
DR   PDB; 6X4N; X-ray; 1.51 A; A=1-165.
DR   PDB; 6X4O; X-ray; 1.50 A; A=1-165.
DR   PDB; 6X4P; X-ray; 1.50 A; A=1-165.
DR   PDB; 6X4Q; X-ray; 1.80 A; A=1-165.
DR   PDB; 6Y9V; EM; 6.90 A; J=2-165.
DR   PDB; 6Y9W; EM; 4.10 A; J=2-165.
DR   PDB; 6Y9X; EM; 4.40 A; J=2-165.
DR   PDB; 6Y9Y; EM; 6.10 A; J=2-165.
DR   PDB; 6Y9Z; EM; 4.80 A; J=2-165.
DR   PDB; 6ZDJ; EM; 5.80 A; J=2-165.
DR   PDB; 7ABT; X-ray; 1.31 A; A=2-164.
DR   PDB; 7N9X; X-ray; 3.51 A; GGG/HHH/III=1-165.
DR   PDB; 7PCJ; X-ray; 1.91 A; A/D=1-165.
DR   PDB; 7QBW; X-ray; 1.59 A; A=1-165.
DR   PDB; 7TA8; NMR; -; A=1-165.
DR   PDB; 7UPN; EM; 3.50 A; A/B=1-165.
DR   PDB; 7UXJ; X-ray; 2.07 A; A/B/C/D=1-165.
DR   PDB; 7UXM; X-ray; 1.20 A; A/B/C=1-165.
DR   PDB; 7UXN; X-ray; 1.36 A; A=1-165.
DR   PDB; 8G9P; X-ray; 1.50 A; C/D=1-165.
DR   PDB; 8G9Q; X-ray; 1.40 A; D=1-165.
DR   PDB; 8HZ8; X-ray; 1.81 A; A=2-165.
DR   PDB; 8TBF; X-ray; 1.50 A; C/D=1-165.
DR   PDB; 8TBG; X-ray; 1.20 A; C/D=1-165.
DR   PDB; 8TBH; X-ray; 1.50 A; C/D=1-165.
DR   PDB; 8TBI; X-ray; 1.59 A; C/D=1-165.
DR   PDB; 8TBJ; X-ray; 1.45 A; C/D=1-165.
DR   PDB; 8TBK; X-ray; 1.26 A; C/D=1-165.
DR   PDB; 8TBL; X-ray; 1.88 A; C/D=1-165.
DR   PDB; 8TBM; X-ray; 1.57 A; C/D=1-165.
DR   PDB; 8TBN; X-ray; 1.46 A; C/D=1-165.
DR   PDB; 9AX6; X-ray; 1.65 A; C/D=1-165.
DR   PDB; 9BFV; X-ray; 1.20 A; C/D=1-165.
DR   PDB; 9BFW; X-ray; 1.20 A; D=1-165.
DR   PDB; 9BFX; X-ray; 1.40 A; C/D=1-165.
DR   PDB; 9BFY; X-ray; 1.26 A; C/D=1-165.
DR   PDB; 9BFZ; X-ray; 1.80 A; C/D=1-165.
DR   PDB; 9BG0; X-ray; 1.64 A; C/D=1-165.
DR   PDB; 9BG1; X-ray; 1.51 A; C/D=1-165.
DR   PDB; 9BG2; X-ray; 1.64 A; C/D=1-165.
DR   PDB; 9BG3; X-ray; 1.33 A; C/D=1-165.
DR   PDB; 9BG4; X-ray; 1.14 A; C/D=1-165.
DR   PDB; 9BG5; X-ray; 1.67 A; C/D=1-165.
DR   PDB; 9BG6; X-ray; 1.66 A; C/D=1-165.
DR   PDB; 9BG7; X-ray; 1.60 A; C/D=1-165.
DR   PDB; 9BG8; X-ray; 1.20 A; C/D=1-165.
DR   PDB; 9BG9; X-ray; 1.58 A; C/D=1-165.
DR   PDB; 9BGA; X-ray; 1.41 A; C/D=1-165.
DR   PDB; 9BGB; X-ray; 1.68 A; C/D=1-165.
DR   PDB; 9BGC; X-ray; 1.87 A; C/D=1-165.
DR   PDB; 9BGD; X-ray; 1.76 A; C/D=1-165.
DR   PDB; 9BHO; X-ray; 1.89 A; B/D=1-165.
DR   PDB; 9BHP; X-ray; 2.10 A; B/D=1-165.
DR   PDB; 9BHQ; X-ray; 1.90 A; B/D=1-165.
DR   PDB; 9BI1; X-ray; 1.65 A; B/D=1-165.
DR   PDB; 9BI2; X-ray; 2.15 A; B/D=1-165.
DR   PDB; 9GHY; X-ray; 1.15 A; A=1-165.
DR   PDBsum; 1AK4; -.
DR   PDBsum; 1AWQ; -.
DR   PDBsum; 1AWR; -.
DR   PDBsum; 1AWS; -.
DR   PDBsum; 1AWT; -.
DR   PDBsum; 1AWU; -.
DR   PDBsum; 1AWV; -.
DR   PDBsum; 1BCK; -.
DR   PDBsum; 1CWA; -.
DR   PDBsum; 1CWB; -.
DR   PDBsum; 1CWC; -.
DR   PDBsum; 1CWF; -.
DR   PDBsum; 1CWH; -.
DR   PDBsum; 1CWI; -.
DR   PDBsum; 1CWJ; -.
DR   PDBsum; 1CWK; -.
DR   PDBsum; 1CWL; -.
DR   PDBsum; 1CWM; -.
DR   PDBsum; 1CWO; -.
DR   PDBsum; 1FGL; -.
DR   PDBsum; 1M63; -.
DR   PDBsum; 1M9C; -.
DR   PDBsum; 1M9D; -.
DR   PDBsum; 1M9E; -.
DR   PDBsum; 1M9F; -.
DR   PDBsum; 1M9X; -.
DR   PDBsum; 1M9Y; -.
DR   PDBsum; 1MF8; -.
DR   PDBsum; 1MIK; -.
DR   PDBsum; 1NMK; -.
DR   PDBsum; 1OCA; -.
DR   PDBsum; 1RMH; -.
DR   PDBsum; 1VBS; -.
DR   PDBsum; 1VBT; -.
DR   PDBsum; 1W8L; -.
DR   PDBsum; 1W8M; -.
DR   PDBsum; 1W8V; -.
DR   PDBsum; 1YND; -.
DR   PDBsum; 1ZKF; -.
DR   PDBsum; 2ALF; -.
DR   PDBsum; 2CPL; -.
DR   PDBsum; 2CYH; -.
DR   PDBsum; 2MS4; -.
DR   PDBsum; 2MZU; -.
DR   PDBsum; 2N0T; -.
DR   PDBsum; 2RMA; -.
DR   PDBsum; 2RMB; -.
DR   PDBsum; 2X25; -.
DR   PDBsum; 2X2A; -.
DR   PDBsum; 2X2C; -.
DR   PDBsum; 2X2D; -.
DR   PDBsum; 2XGY; -.
DR   PDBsum; 3CYH; -.
DR   PDBsum; 3CYS; -.
DR   PDBsum; 3K0M; -.
DR   PDBsum; 3K0N; -.
DR   PDBsum; 3K0O; -.
DR   PDBsum; 3K0P; -.
DR   PDBsum; 3K0Q; -.
DR   PDBsum; 3K0R; -.
DR   PDBsum; 3ODI; -.
DR   PDBsum; 3ODL; -.
DR   PDBsum; 3RDD; -.
DR   PDBsum; 4CYH; -.
DR   PDBsum; 4IPZ; -.
DR   PDBsum; 4N1M; -.
DR   PDBsum; 4N1N; -.
DR   PDBsum; 4N1O; -.
DR   PDBsum; 4N1P; -.
DR   PDBsum; 4N1Q; -.
DR   PDBsum; 4N1R; -.
DR   PDBsum; 4N1S; -.
DR   PDBsum; 4YUG; -.
DR   PDBsum; 4YUH; -.
DR   PDBsum; 4YUI; -.
DR   PDBsum; 4YUJ; -.
DR   PDBsum; 4YUK; -.
DR   PDBsum; 4YUL; -.
DR   PDBsum; 4YUM; -.
DR   PDBsum; 4YUN; -.
DR   PDBsum; 4YUO; -.
DR   PDBsum; 4YUP; -.
DR   PDBsum; 5CYH; -.
DR   PDBsum; 5F66; -.
DR   PDBsum; 5FJB; -.
DR   PDBsum; 5KUL; -.
DR   PDBsum; 5KUN; -.
DR   PDBsum; 5KUO; -.
DR   PDBsum; 5KUQ; -.
DR   PDBsum; 5KUR; -.
DR   PDBsum; 5KUS; -.
DR   PDBsum; 5KUU; -.
DR   PDBsum; 5KUV; -.
DR   PDBsum; 5KUW; -.
DR   PDBsum; 5KUZ; -.
DR   PDBsum; 5KV0; -.
DR   PDBsum; 5KV1; -.
DR   PDBsum; 5KV2; -.
DR   PDBsum; 5KV3; -.
DR   PDBsum; 5KV4; -.
DR   PDBsum; 5KV5; -.
DR   PDBsum; 5KV6; -.
DR   PDBsum; 5KV7; -.
DR   PDBsum; 5LUD; -.
DR   PDBsum; 5NOQ; -.
DR   PDBsum; 5NOR; -.
DR   PDBsum; 5NOS; -.
DR   PDBsum; 5NOT; -.
DR   PDBsum; 5NOU; -.
DR   PDBsum; 5NOV; -.
DR   PDBsum; 5NOW; -.
DR   PDBsum; 5NOX; -.
DR   PDBsum; 5NOY; -.
DR   PDBsum; 5NOZ; -.
DR   PDBsum; 5T9U; -.
DR   PDBsum; 5T9W; -.
DR   PDBsum; 5T9Z; -.
DR   PDBsum; 5TA2; -.
DR   PDBsum; 5TA4; -.
DR   PDBsum; 5WC7; -.
DR   PDBsum; 6BTA; -.
DR   PDBsum; 6GJI; -.
DR   PDBsum; 6GJJ; -.
DR   PDBsum; 6GJL; -.
DR   PDBsum; 6GJM; -.
DR   PDBsum; 6GJN; -.
DR   PDBsum; 6GJP; -.
DR   PDBsum; 6GJR; -.
DR   PDBsum; 6GJY; -.
DR   PDBsum; 6GS6; -.
DR   PDBsum; 6I42; -.
DR   PDBsum; 6U5C; -.
DR   PDBsum; 6U5D; -.
DR   PDBsum; 6U5E; -.
DR   PDBsum; 6U5G; -.
DR   PDBsum; 6X3R; -.
DR   PDBsum; 6X3Y; -.
DR   PDBsum; 6X4M; -.
DR   PDBsum; 6X4N; -.
DR   PDBsum; 6X4O; -.
DR   PDBsum; 6X4P; -.
DR   PDBsum; 6X4Q; -.
DR   PDBsum; 6Y9V; -.
DR   PDBsum; 6Y9W; -.
DR   PDBsum; 6Y9X; -.
DR   PDBsum; 6Y9Y; -.
DR   PDBsum; 6Y9Z; -.
DR   PDBsum; 6ZDJ; -.
DR   PDBsum; 7ABT; -.
DR   PDBsum; 7N9X; -.
DR   PDBsum; 7PCJ; -.
DR   PDBsum; 7QBW; -.
DR   PDBsum; 7TA8; -.
DR   PDBsum; 7UPN; -.
DR   PDBsum; 7UXJ; -.
DR   PDBsum; 7UXM; -.
DR   PDBsum; 7UXN; -.
DR   PDBsum; 8G9P; -.
DR   PDBsum; 8G9Q; -.
DR   PDBsum; 8HZ8; -.
DR   PDBsum; 8TBF; -.
DR   PDBsum; 8TBG; -.
DR   PDBsum; 8TBH; -.
DR   PDBsum; 8TBI; -.
DR   PDBsum; 8TBJ; -.
DR   PDBsum; 8TBK; -.
DR   PDBsum; 8TBL; -.
DR   PDBsum; 8TBM; -.
DR   PDBsum; 8TBN; -.
DR   PDBsum; 9AX6; -.
DR   PDBsum; 9BFV; -.
DR   PDBsum; 9BFW; -.
DR   PDBsum; 9BFX; -.
DR   PDBsum; 9BFY; -.
DR   PDBsum; 9BFZ; -.
DR   PDBsum; 9BG0; -.
DR   PDBsum; 9BG1; -.
DR   PDBsum; 9BG2; -.
DR   PDBsum; 9BG3; -.
DR   PDBsum; 9BG4; -.
DR   PDBsum; 9BG5; -.
DR   PDBsum; 9BG6; -.
DR   PDBsum; 9BG7; -.
DR   PDBsum; 9BG8; -.
DR   PDBsum; 9BG9; -.
DR   PDBsum; 9BGA; -.
DR   PDBsum; 9BGB; -.
DR   PDBsum; 9BGC; -.
DR   PDBsum; 9BGD; -.
DR   PDBsum; 9BHO; -.
DR   PDBsum; 9BHP; -.
DR   PDBsum; 9BHQ; -.
DR   PDBsum; 9BI1; -.
DR   PDBsum; 9BI2; -.
DR   PDBsum; 9GHY; -.
DR   AlphaFoldDB; P62937; -.
DR   BMRB; P62937; -.
DR   EMDB; EMD-10738; -.
DR   EMDB; EMD-10739; -.
DR   EMDB; EMD-10740; -.
DR   EMDB; EMD-10741; -.
DR   EMDB; EMD-10742; -.
DR   EMDB; EMD-11176; -.
DR   EMDB; EMD-20645; -.
DR   EMDB; EMD-26673; -.
DR   SMR; P62937; -.
DR   BioGRID; 111474; 914.
DR   CORUM; P62937; -.
DR   DIP; DIP-6080N; -.
DR   FunCoup; P62937; 1583.
DR   IntAct; P62937; 194.
DR   MINT; P62937; -.
DR   STRING; 9606.ENSP00000419425; -.
DR   BindingDB; P62937; -.
DR   ChEMBL; CHEMBL1949; -.
DR   DrugBank; DB01742; (3r)-1-Acetyl-3-Methylpiperidine.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB08168; Coumarin 120.
DR   DrugBank; DB00091; Cyclosporine.
DR   DrugBank; DB02419; Ethyl Oxo(Piperidin-1-Yl)Acetate.
DR   DrugBank; DB00172; Proline.
DR   DrugBank; DB03393; Sanglifehrin A.
DR   DrugCentral; P62937; -.
DR   GuidetoPHARMACOLOGY; 2751; -.
DR   GlyCosmos; P62937; 2 sites, 2 glycans.
DR   GlyGen; P62937; 3 sites, 6 N-linked glycans (2 sites), 2 O-linked glycans (1 site).
DR   iPTMnet; P62937; -.
DR   MetOSite; P62937; -.
DR   PhosphoSitePlus; P62937; -.
DR   SwissPalm; P62937; -.
DR   BioMuta; PPIA; -.
DR   DMDM; 51702775; -.
DR   OGP; P62937; -.
DR   REPRODUCTION-2DPAGE; IPI00419585; -.
DR   REPRODUCTION-2DPAGE; P62937; -.
DR   jPOST; P62937; -.
DR   MassIVE; P62937; -.
DR   PaxDb; 9606-ENSP00000419425; -.
DR   PeptideAtlas; P62937; -.
DR   PRIDE; P62937; -.
DR   ProteomicsDB; 57455; -. [P62937-1]
DR   ProteomicsDB; 62564; -.
DR   Pumba; P62937; -.
DR   TopDownProteomics; P62937-1; -. [P62937-1]
DR   ABCD; P62937; 2 sequenced antibodies.
DR   Antibodypedia; 13466; 676 antibodies from 44 providers.
DR   DNASU; 5478; -.
DR   Ensembl; ENST00000355968.10; ENSP00000430817.1; ENSG00000196262.16. [P62937-2]
DR   Ensembl; ENST00000468812.6; ENSP00000419425.1; ENSG00000196262.16. [P62937-1]
DR   Ensembl; ENST00000489459.5; ENSP00000427976.1; ENSG00000196262.16. [P62937-2]
DR   Ensembl; ENST00000677022.1; ENSP00000504216.1; ENSG00000196262.16. [P62937-2]
DR   Ensembl; ENST00000677107.1; ENSP00000504735.1; ENSG00000196262.16. [P62937-2]
DR   Ensembl; ENST00000678789.1; ENSP00000503804.1; ENSG00000196262.16. [P62937-2]
DR   Ensembl; ENST00000678805.1; ENSP00000502945.1; ENSG00000196262.16. [P62937-2]
DR   GeneID; 5478; -.
DR   KEGG; hsa:5478; -.
DR   MANE-Select; ENST00000468812.6; ENSP00000419425.1; NM_021130.5; NP_066953.1.
DR   UCSC; uc064djo.1; human. [P62937-1]
DR   AGR; HGNC:9253; -.
DR   ClinPGx; PA33574; -.
DR   CTD; 5478; -.
DR   DisGeNET; 5478; -.
DR   GeneCards; PPIA; -.
DR   HGNC; HGNC:9253; PPIA.
DR   HPA; ENSG00000196262; Low tissue specificity.
DR   MIM; 123840; gene.
DR   OpenTargets; ENSG00000196262; -.
DR   VEuPathDB; HostDB:ENSG00000196262; -.
DR   eggNOG; KOG0865; Eukaryota.
DR   GeneTree; ENSGT00950000183087; -.
DR   HOGENOM; CLU_012062_38_0_1; -.
DR   InParanoid; P62937; -.
DR   OMA; CVSIYGH; -.
DR   OrthoDB; 9753748at2759; -.
DR   PAN-GO; P62937; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P62937; -.
DR   BRENDA; 5.2.1.8; 2681.
DR   PathwayCommons; P62937; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-162585; Uncoating of the HIV Virion.
DR   Reactome; R-HSA-162588; Budding and maturation of HIV virion.
DR   Reactome; R-HSA-162592; Integration of provirus.
DR   Reactome; R-HSA-162594; Early Phase of HIV Life Cycle.
DR   Reactome; R-HSA-164516; Minus-strand DNA synthesis.
DR   Reactome; R-HSA-164525; Plus-strand DNA synthesis.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-175474; Assembly Of The HIV Virion.
DR   Reactome; R-HSA-180689; APOBEC3G mediated resistance to HIV-1 infection.
DR   Reactome; R-HSA-2025928; Calcineurin activates NFAT.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses.
DR   SignaLink; P62937; -.
DR   Agora; ENSG00000196262; -.
DR   BioGRID-ORCS; 5478; 552 hits in 1129 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; PPIA; human.
DR   EvolutionaryTrace; P62937; -.
DR   GeneWiki; Peptidylprolyl_isomerase_A; -.
DR   GenomeRNAi; 5478; -.
DR   Pharos; P62937; Tclin.
DR   PRO; PR:P62937; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P62937; protein.
DR   Bgee; ENSG00000196262; Expressed in ventricular zone and 180 other cell types or tissues.
DR   ExpressionAtlas; P62937; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; HDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0016018; F:cyclosporin A binding; IBA:GO_Central.
DR   GO; GO:1904399; F:heparan sulfate binding; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; ISS:UniProtKB.
DR   GO; GO:0003755; F:peptidyl-prolyl cis-trans isomerase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:UniProtKB.
DR   GO; GO:0046790; F:virion binding; NAS:UniProtKB.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0060352; P:cell adhesion molecule production; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0042118; P:endothelial cell activation; IDA:UniProtKB.
DR   GO; GO:0030595; P:leukocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0034389; P:lipid droplet organization; IMP:UniProtKB.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0061944; P:negative regulation of protein K48-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IMP:UniProtKB.
DR   GO; GO:1903901; P:negative regulation of viral life cycle; IMP:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; ISS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0000413; P:protein peptidyl-prolyl isomerization; IDA:UniProtKB.
DR   GO; GO:2001233; P:regulation of apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045069; P:regulation of viral genome replication; IMP:UniProtKB.
DR   GO; GO:0019076; P:viral release from host cell; TAS:UniProtKB.
DR   CDD; cd01926; cyclophilin_ABH_like; 1.
DR   FunFam; 2.40.100.10:FF:000011; Peptidyl-prolyl cis-trans isomerase A; 1.
DR   Gene3D; 2.40.100.10; Cyclophilin-like; 1.
DR   InterPro; IPR029000; Cyclophilin-like_dom_sf.
DR   InterPro; IPR024936; Cyclophilin-type_PPIase.
DR   InterPro; IPR020892; Cyclophilin-type_PPIase_CS.
DR   InterPro; IPR002130; Cyclophilin-type_PPIase_dom.
DR   PANTHER; PTHR11071; PEPTIDYL-PROLYL CIS-TRANS ISOMERASE; 1.
DR   PANTHER; PTHR11071:SF490; PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A; 1.
DR   Pfam; PF00160; Pro_isomerase; 1.
DR   PIRSF; PIRSF001467; Peptidylpro_ismrse; 1.
DR   PRINTS; PR00153; CSAPPISMRASE.
DR   SUPFAM; SSF50891; Cyclophilin-like; 1.
DR   PROSITE; PS00170; CSA_PPIASE_1; 1.
DR   PROSITE; PS50072; CSA_PPIASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Cell membrane;
KW   Cytoplasm; Direct protein sequencing; Glycoprotein; Host-virus interaction;
KW   Isomerase; Isopeptide bond; Membrane; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Rotamase; Secreted;
KW   Ubl conjugation.
FT   CHAIN           1..165
FT                   /note="Peptidyl-prolyl cis-trans isomerase A"
FT                   /id="PRO_0000423240"
FT   INIT_MET        1
FT                   /note="Removed; alternate"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:25489052, ECO:0000269|PubMed:7657784,
FT                   ECO:0000269|Ref.11, ECO:0000269|Ref.12,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           2..165
FT                   /note="Peptidyl-prolyl cis-trans isomerase A, N-terminally
FT                   processed"
FT                   /id="PRO_0000064115"
FT   DOMAIN          7..163
FT                   /note="PPIase cyclophilin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00156"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         2
FT                   /note="N-acetylvaline; partial; in Peptidyl-prolyl cis-
FT                   trans isomerase A, N-terminally processed"
FT                   /evidence="ECO:0000269|PubMed:25489052, ECO:0000269|Ref.12,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:25944712"
FT   MOD_RES         28
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         44
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         76
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         82
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         93
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         125
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20364129,
FT                   ECO:0000269|PubMed:25678563, ECO:0007744|PubMed:19608861"
FT   MOD_RES         131
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         133
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P17742"
FT   CARBOHYD        108
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        28
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        28
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT   CROSSLNK        82
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..60
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056050"
FT   MUTAGEN         55
FT                   /note="R->A: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity. No loss of its interaction with BSG/CD147 or its
FT                   ability to induce leukocyte chemotaxis. No effect on its
FT                   interaction with MAP3K5/ASK1. Loss of its ability to
FT                   negatively regulate oxidative stress-induced apoptosis
FT                   mediated by MAP3K5/ASK1. Reduced interaction with TARDBP.
FT                   No loss of interaction with influenza A virus matrix
FT                   protein 1 or its ability to inhibit viral replication."
FT                   /evidence="ECO:0000269|PubMed:19207730,
FT                   ECO:0000269|PubMed:21245143, ECO:0000269|PubMed:25678563,
FT                   ECO:0000269|PubMed:26095851"
FT   MUTAGEN         60
FT                   /note="F->A: Loss of ability to stimulate MAPK/ERK
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775"
FT   MUTAGEN         69
FT                   /note="R->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         70
FT                   /note="H->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         107
FT                   /note="T->A: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity. Reduced interaction with BSG/CD147 and
FT                   ability to induce leukocyte chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:21245143"
FT   MUTAGEN         113
FT                   /note="F->A: Reduced ability to stimulate MAPK/ERK
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775"
FT   MUTAGEN         121
FT                   /note="W->A: 200-fold decrease of sensitivity to CsA.
FT                   Reduced ability to stimulate MAPK/ERK phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775,
FT                   ECO:0000269|PubMed:2001362"
FT   MUTAGEN         121
FT                   /note="W->E: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:20676357"
FT   MUTAGEN         121
FT                   /note="W->F: 75-fold decrease of sensitivity to CsA."
FT                   /evidence="ECO:0000269|PubMed:2001362"
FT   MUTAGEN         121
FT                   /note="W->H: No effect on peptidyl-prolyl cis-trans
FT                   isomerase activity."
FT                   /evidence="ECO:0000269|PubMed:20676357"
FT   MUTAGEN         125
FT                   /note="K->Q: Acetylation-mimetic mutant; no effect on its
FT                   interaction with TARDBP."
FT                   /evidence="ECO:0000269|PubMed:25678563"
FT   MUTAGEN         125
FT                   /note="K->R: Loss of acetylation and interaction with
FT                   TARDBP."
FT                   /evidence="ECO:0000269|PubMed:25678563"
FT   MUTAGEN         126
FT                   /note="H->A: Loss of peptidyl-prolyl cis-trans isomerase
FT                   activity and interaction with HCVNS5A. Loss of ability to
FT                   stimulate MAPK/ERK phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11943775,
FT                   ECO:0000269|PubMed:21593166"
FT   CONFLICT        89
FT                   /note="I -> T (in Ref. 8; AAH05982)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        106
FT                   /note="N -> I (in Ref. 8; AAH07104)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="E -> D (in Ref. 4; CAG32988)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..12
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          15..24
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   TURN            26..28
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   HELIX           30..41
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   TURN            42..44
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   TURN            58..60
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          61..64
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   TURN            67..69
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          70..73
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          74..77
FT                   /evidence="ECO:0007829|PDB:2MS4"
FT   STRAND          78..81
FT                   /evidence="ECO:0007829|PDB:4YUI"
FT   STRAND          97..100
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          102..104
FT                   /evidence="ECO:0007829|PDB:6I42"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:7ABT"
FT   STRAND          112..117
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   HELIX           120..122
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          128..134
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   HELIX           136..143
FT                   /evidence="ECO:0007829|PDB:4N1M"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:7UXN"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:2MS4"
FT   STRAND          156..164
FT                   /evidence="ECO:0007829|PDB:4N1M"
SQ   SEQUENCE   165 AA;  18012 MW;  9B2E637A555E4434 CRC64;
     MVNPTVFFDI AVDGEPLGRV SFELFADKVP KTAENFRALS TGEKGFGYKG SCFHRIIPGF
     MCQGGDFTRH NGTGGKSIYG EKFEDENFIL KHTGPGILSM ANAGPNTNGS QFFICTAKTE
     WLDGKHVVFG KVKEGMNIVE AMERFGSRNG KTSKKITIAD CGQLE
//
